XORTX Therapeutics (XRTX) announced the initiation of Investigational New Drug, IND, preparation for its lead program, XRx-026, focused on the treatment of gout. In support of this milestone, XORTX has engaged Allucent, a global contract research organization specializing in regulatory and clinical development. Preparation of the IND will include a comprehensive review of non-clinical, pharmacologic, toxicological, and regulatory progress, and will incorporate the clinical development plan and protocol for a pharmacologic characterization study of XORLO, the Company’s proprietary formulation of oxypurinol, in fed and fasted states. XORTX anticipates submission of the IND in the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Therapeutics Reports Financial Results for Mid-2025
- XORTX Therapeutics Completes $114,500 Private Placement to Fund Gout Programs
- Xortx Therapeutics announces planned goals for 2026
- XORTX Therapeutics Advances Gout Program with Strategic 2025/2026 Goals
- XORTX Therapeutics Announces $114,500 Private Placement to Support Gout Programs